Cumberland To Co-Commercialize Talicia With RedHill, For The Treatment Of Helicobacter Pylori Infection In Adults, A Bacterial Infection And Leading Risk Factor For Gastric Cancer

 Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy

NASHVILLE, Tenn., Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd. (NASDAQ:RDHL), a specialty biopharmaceutical company, to jointly commercialize Talicia®. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer.

Under the terms of the agreement, Cumberland and RedHill will form a new, jointly owned company. RedHill will contribute all its Talicia assets to the new company including the product's growing international licenses with associated revenues. Cumberland will provide $4 million in investment capital.  Cumberland will assume responsibility for the product's distribution and record the product sales. Talicia net revenues were $8 million in 2024.  The two companies will equally share in those net revenues and collaborate on all operational aspects, including sales, marketing, manufacturing, regulatory and supply chain functions. Through this co-commercialization agreement, Cumberland will leverage its established national field sales force to lead promotional efforts for Talicia and expand its reach among office based healthcare providers.